Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| MRNA | Moderna, Inc. | -6.72% | 174.07 | 0.0% | $1639.17m | |
| NVAX | Novavax, Inc. | -6.21% | 92.33 | 78.2% | $633.32m | |
| AMGN | Amgen, Inc. | -1.08% | 231.30 | 1.4% | $520.34m | |
| BIIB | Biogen, Inc. | -1.28% | 230.81 | 1.8% | $499.50m | |
| GILD | Gilead Sciences, Inc. | -1.93% | 69.07 | 1.0% | $465.79m | |
| BNTX | BioNTech SE | -4.47% | 161.66 | 0.0% | $438.57m | |
| REGN | Regeneron Pharmaceuticals, Inc. | 1.13% | 618.11 | 2.7% | $392.67m | |
| ILMN | Illumina, Inc. | 0.32% | 384.36 | 3.3% | $386.08m | |
| VRTX | Vertex Pharmaceuticals, Inc. | -0.10% | 230.84 | 1.9% | $334.35m | |
| SNSS | Sunesis Pharmaceuticals, Inc. | -4.00% | 2.88 | 0.7% | $201.32m | |
| EXAS | EXACT Sciences Corp. | -1.67% | 76.13 | 17.9% | $160.64m | |
| ARNA | Arena Pharmaceuticals, Inc. | -0.51% | 91.51 | 13.7% | $138.71m | |
| ALNY | Alnylam Pharmaceuticals, Inc. | -0.41% | 138.62 | 8.2% | $131.51m | |
| INCY | Incyte Corp. | -0.31% | 74.78 | 2.4% | $129.60m | |
| BBIO | BridgeBio Pharma, Inc. | -0.51% | 11.70 | 0.0% | $104.26m |
Company Profile
Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the following segments: Protein Sciences and Diagnostics &Genomics. The Protein Sciences segment develops and manufactures purified proteins and reagent solutions most notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents and T-Cell activation technologies. This segment also includes protein analysis solutions that offer researchers efficient and streamlined options for automated western blot and multiplexed ELISA workflow. The Diagnostics &Genomics segment develops and manufactures diagnostic products, including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM and clinical customers, as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx Prostate(IntelliScore) test (EPI) for prostate cancer diagnosis. This segment also manufactures and sells advanced tissue-based in-situ hybridization assays (ISH) for research and clinical use. The company was founded in 1976 and is headquartered in Minneapolis, MN.